高级检索
当前位置: 首页 > 详情页

The comparison of survival between active surveillance or watchful waiting and focal laser ablation in patients with low-risk prostate cancer.

文献详情

资源类型:
Pubmed体系:

收录情况: ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越:梯队期刊

机构: [1]Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu 610041, China. [2]Department of Biotherapy, Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China.
出处:
ISSN:

摘要:
Prostate cancer (PCa) is the second-most common cancer among men. Both active surveillance or watchful waiting (AS/WW) and focal laser ablation (FLA) can avoid the complications caused by radical treatment. How to make the choice between these options in clinical practice needs further study. Therefore, this study aims to compare and analyze their effects based on overall survival (OS) and cancer-specific survival (CSS) to obtain better long-term benefits. We included patients with low-risk PCa from the Surveillance Epidemiology and End Results database of 2010-2016. Multivariate Cox proportional hazard analyses were conducted for OS and CSS in the two groups. To eliminate bias, this study applied a series of sensitivity analyses. Moreover, Kaplan-Meier curves were plotted to obtain survival status. A total of 18 841 patients with low-risk PCa were included, with a median of 36-month follow-up. According to the multivariate Cox proportional hazard regression, the FLA group presented inferior survival benefits in OS than the AS/WW group (hazard ratio [HR]: 2.13, 95% confidence interval [CI]: 1.37-3.33, P < 0.05). After adjusting for confounders, the result persisted (HR: 1.69, 95% CI: 1.02-2.81, P < 0.05). According to the results of the sensitivity analysis, the inverse probability of the treatment weighing model indicated the same result in OS. In conclusion, AS/WW and FLA have the advantage of fewer side effects and the benefit of avoiding overtreatment compared with standard treatment. Our study suggested that AS/WW provides more survival benefits for patients with low-risk PCa. More relevant researches and data will be needed for further clarity.

语种:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 2 区 医学
小类 | 2 区 男科学 2 区 泌尿学与肾脏学
最新[2023]版:
大类 | 2 区 医学
小类 | 3 区 男科学 3 区 泌尿学与肾脏学
第一作者:
第一作者机构: [1]Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu 610041, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:46861 今日访问量:0 总访问量:3333 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号